{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:23:27Z","timestamp":1787977407569,"version":"build-2784847793"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00228-025-03809-7","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:51:35Z","timestamp":1739523095000},"page":"525-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2052-439X","authenticated-orcid":false,"given":"Anan","family":"Jarab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-7572","authenticated-orcid":false,"given":"Walid","family":"Al-Qerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0132-1086","authenticated-orcid":false,"given":"Adam","family":"Khdour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-7158","authenticated-orcid":false,"given":"Heba","family":"Awadallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0209-3050","authenticated-orcid":false,"given":"Yousef","family":"Mimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-7922","authenticated-orcid":false,"given":"Maher","family":"Khdour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"2","key":"3809_CR1","first-page":"2","volume":"3","author":"G Ayano","year":"2016","unstructured":"Ayano G (2016) Schizophrenia: a concise overview of etiology, epidemiology diagnosis and management: review of literatures. J Schizophrenia Res 3(2):2\u20137","journal-title":"J Schizophrenia Res"},{"issue":"1","key":"3809_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.schres.2013.07.009","volume":"150","author":"J Schaefer","year":"2013","unstructured":"Schaefer J, Giangrande E, Weinberger DR, Dickinson D (2013) The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res 150(1):42\u201350","journal-title":"Schizophr Res"},{"key":"3809_CR3","doi-asserted-by":"crossref","unstructured":"P. M. Haddad, C. Brain, and J. Scott, \u201cNonadherence with antipsychotic medication in schizophrenia: challenges and management strategies,\u201d Patient related outcome measures, pp. 43\u201362, 2014.","DOI":"10.2147\/PROM.S42735"},{"issue":"12","key":"3809_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog L, Fleischhacker W, Lieberman J (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17(12):1206\u20131227","journal-title":"Mol Psychiatry"},{"issue":"8","key":"3809_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/biom14080906","volume":"14","author":"CU Correll","year":"2024","unstructured":"Correll CU, Tusconi M, Carta MG, Dursun SM (2024) What remains to be discovered in schizophrenia therapeutics: contributions by advancing the molecular mechanisms of drugs for psychosis and schizophrenia. Biomolecules 14(8):906","journal-title":"Biomolecules"},{"issue":"11","key":"3809_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/ph13110365","volume":"13","author":"SA Torrisi","year":"2020","unstructured":"Torrisi SA et al (2020) Dopamine, cognitive impairments and second-generation antipsychotics: from mechanistic advances to more personalized treatments. Pharmaceuticals 13(11):365","journal-title":"Pharmaceuticals"},{"key":"3809_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","volume":"192","author":"S Aringhieri","year":"2018","unstructured":"Aringhieri S et al (2018) Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 192:20\u201341","journal-title":"Pharmacol Ther"},{"key":"3809_CR8","doi-asserted-by":"crossref","unstructured":"M. Solmi et al., \u201cSafety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review,\u201d Therapeutics and clinical risk management, pp. 757\u2013777, 2017.","DOI":"10.2147\/TCRM.S117321"},{"issue":"6","key":"3809_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","volume":"15","author":"MD Brennan","year":"2014","unstructured":"Brennan MD (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15(6):869\u2013884","journal-title":"Pharmacogenomics"},{"key":"3809_CR10","first-page":"217","volume":"2","author":"A Rezaei","year":"2022","unstructured":"Rezaei A (2022) Schizophrenia: mechanisms and neurotransmitters. Eurasian Journal of Science and Technology 2:217\u2013229","journal-title":"Eurasian Journal of Science and Technology"},{"issue":"3\u20134","key":"3809_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","volume":"83","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Javitt DC (2010) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83(3\u20134):108\u2013121","journal-title":"Brain Res Bull"},{"key":"3809_CR12","doi-asserted-by":"crossref","unstructured":"O. Gruber, A. Chadha Santuccione, and H. Aach, \u201cMagnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system,\u201d Frontiers in psychiatry, vol. 5, p. 32, 2014.","DOI":"10.3389\/fpsyt.2014.00032"},{"issue":"9","key":"3809_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","volume":"179","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC (2022) Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry 179(9):611\u2013627","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3809_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1021\/cn200110q","volume":"3","author":"D Dencker","year":"2012","unstructured":"Dencker D et al (2012) Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse, and Parkinson\u2019s disease. ACS Chem Neurosci 3(2):80\u201389","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"3809_CR15","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.3390\/ijms19103105","volume":"19","author":"M Kondej","year":"2018","unstructured":"Kondej M, St\u0119pnicki P, Kaczor AA (2018) Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci 19(10):3105","journal-title":"Int J Mol Sci"},{"key":"3809_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/bs.apha.2019.05.001","volume":"86","author":"LB Teal","year":"2019","unstructured":"Teal LB, Gould RW, Felts AS, Jones CK (2019) Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Adv Pharmacol 86:153\u2013196","journal-title":"Adv Pharmacol"},{"issue":"1","key":"3809_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","volume":"13","author":"ML Heffernan","year":"2021","unstructured":"Heffernan ML et al (2021) Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett 13(1):92\u201398","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"3809_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/13543784.2023.2206559","volume":"32","author":"GH Le","year":"2023","unstructured":"Le GH et al (2023) Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opin Investig Drugs 32(5):401\u2013415","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"3809_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00406-023-01580-3","volume":"273","author":"ED Achtyes","year":"2023","unstructured":"Achtyes ED, Hopkins SC, Dedic N, Dworak H, Zeni C, Koblan K (2023) Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci 273(7):1543\u20131556","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"9","key":"3809_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40263-020-00752-2","volume":"34","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz JT (2020) Targeting serotonin 5-HT2A receptors to better treat schizophrenia: rationale and current approaches. CNS Drugs 34(9):947\u2013959","journal-title":"CNS Drugs"},{"key":"3809_CR21","doi-asserted-by":"publisher","first-page":"115028","DOI":"10.1016\/j.bcp.2022.115028","volume":"200","author":"AB Casey","year":"2022","unstructured":"Casey AB, Cui M, Booth RG, Canal CE (2022) \u201cSelective\u201d serotonin 5-HT2A receptor antagonists. Biochem Pharmacol 200:115028","journal-title":"Biochem Pharmacol"},{"key":"3809_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fphar.2020.00591","volume":"11","author":"OB Baltzersen","year":"2020","unstructured":"Baltzersen OB et al (2020) Identification of a serotonin 2A receptor subtype of schizophrenia spectrum disorders with pimavanserin: the sub-sero proof-of-concept trial protocol. Front Pharmacol 11:591","journal-title":"Front Pharmacol"},{"issue":"19","key":"3809_CR23","doi-asserted-by":"publisher","first-page":"10668","DOI":"10.3390\/ijms251910668","volume":"25","author":"T Zhang","year":"2024","unstructured":"Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X (2024) Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways. Int J Mol Sci 25(19):10668","journal-title":"Int J Mol Sci"},{"key":"3809_CR24","doi-asserted-by":"crossref","unstructured":"P. Dudzik, K. Lustyk, and K. Pytka, \u201cBeyond dopamine: novel strategies for schizophrenia treatment,\u201d Medicinal Research Reviews, 2024.","DOI":"10.1002\/med.22042"},{"key":"3809_CR25","doi-asserted-by":"crossref","unstructured":"A. Vita, G. Nibbio, and S. Barlati, \u201cPharmacological treatment of cognitive impairment associated with schizophrenia: state of the art and future perspectives,\u201d Schizophrenia Bulletin Open, p. sgae013, 2024.","DOI":"10.1093\/schizbullopen\/sgae013"},{"issue":"1","key":"3809_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/mp.2013.136","volume":"19","author":"E Poels","year":"2014","unstructured":"Poels E et al (2014) Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 19(1):20\u201329","journal-title":"Mol Psychiatry"},{"issue":"8","key":"3809_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/brainsci13081193","volume":"13","author":"EM Tsapakis","year":"2023","unstructured":"Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN (2023) Novel compounds in the treatment of schizophrenia\u2014a selective review. Brain Sci 13(8):1193","journal-title":"Brain Sci"},{"issue":"8","key":"3809_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 384(8):717\u2013726","journal-title":"N Engl J Med"},{"key":"3809_CR29","doi-asserted-by":"crossref","unstructured":"I. Kaul et al., \u201cEfficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial,\u201d JAMA psychiatry, 2024.","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"issue":"1","key":"3809_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","volume":"12","author":"C Sauder","year":"2022","unstructured":"Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK (2022) Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry 12(1):491","journal-title":"Transl Psychiatry"},{"issue":"1","key":"3809_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Angelov AS, Miller AC, Weiden PJ, Brannan SK (2022) Safety and tolerability of KarXT (xanomeline\u2013trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia 8(1):109","journal-title":"Schizophrenia"},{"issue":"10369","key":"3809_CR32","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH et al (2022) Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet 400(10369):2210\u20132220","journal-title":"The Lancet"},{"issue":"1","key":"3809_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","volume":"9","author":"D Bugarski-Kirola","year":"2022","unstructured":"Bugarski-Kirola D et al (2022) Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. The Lancet Psychiatry 9(1):46\u201358","journal-title":"The Lancet Psychiatry"},{"issue":"6","key":"3809_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/JCP.0000000000001611","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M et al (2022) Pimavanserin exposure-response analyses in patients with schizophrenia: results from the Phase 2 ADVANCE Study. J Clin Psychopharmacol 42(6):544\u2013551","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3809_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D et al (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiat 71(6):637\u2013646","journal-title":"JAMA Psychiat"},{"issue":"3","key":"3809_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW et al (2021) Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet Psychiatry 8(3):191\u2013201","journal-title":"The Lancet Psychiatry"},{"key":"3809_CR37","doi-asserted-by":"crossref","unstructured":"C. U. Correll et al., \u201cSafety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study,\u201d npj Schizophrenia, vol. 7, no. 1, p. 63, 2021.","DOI":"10.1038\/s41537-021-00190-z"},{"issue":"12","key":"3809_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"D Bugarski-Kirola","year":"2016","unstructured":"Bugarski-Kirola D et al (2016) Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. The Lancet Psychiatry 3(12):1115\u20131128","journal-title":"The Lancet Psychiatry"},{"key":"3809_CR39","doi-asserted-by":"crossref","unstructured":"A. Azargoonjahromi, \u201cCurrent findings and potential mechanisms of KarXT (xanomeline\u2013trospium) in schizophrenia treatment,\u201d Clinical Drug Investigation, pp. 1\u201323, 2024.","DOI":"10.1007\/s40261-024-01377-9"},{"issue":"8","key":"3809_CR40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A et al (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165(8):1033\u20131039","journal-title":"Am J Psychiatry"},{"key":"3809_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","volume":"92","author":"N Fabiano","year":"2025","unstructured":"Fabiano N, Wong S, Zhou C, Correll CU, H\u00f8jlund M, Solmi M (2025) Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol 92:62\u201373","journal-title":"Eur Neuropsychopharmacol"},{"key":"3809_CR42","doi-asserted-by":"crossref","unstructured":"C. M. Smith et al., \u201cXanomeline-trospium (Cobenfy TM) for schizophrenia: a review of the literature,\u201d 2024.","DOI":"10.9758\/cpn.24.1253"},{"issue":"4","key":"3809_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/14656566.2024.2334424","volume":"25","author":"A Leber","year":"2024","unstructured":"Leber A et al (2024) Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opin Pharmacother 25(4):467\u2013476","journal-title":"Expert Opin Pharmacother"},{"issue":"18","key":"3809_CR44","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1517\/14656560802532707","volume":"9","author":"A Abbas","year":"2008","unstructured":"Abbas A, Roth BL (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 9(18):3251\u20133259","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"3809_CR45","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1517\/14656566.2013.819345","volume":"14","author":"JH Friedman","year":"2013","unstructured":"Friedman JH (2013) Pimavanserin for the treatment of Parkinson\u2019s disease psychosis. Expert Opin Pharmacother 14(14):1969\u20131975","journal-title":"Expert Opin Pharmacother"},{"key":"3809_CR46","unstructured":"N. V. Cruz, \u201cSystematic review and meta-analysis of pimavanserin and volinanserin in schizophrenia treatment,\u201d 2022."},{"issue":"13","key":"3809_CR47","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/14656566.2021.1942455","volume":"22","author":"J Davis","year":"2021","unstructured":"Davis J, Zamora D, Horowitz M, Leucht S (2021) Evaluating pimavanserin as a treatment for psychiatric disorders: a pharmacological property in search of an indication. Expert Opin Pharmacother 22(13):1651\u20131660","journal-title":"Expert Opin Pharmacother"},{"key":"3809_CR48","unstructured":"F. Madhuri, \u201cEffect of pimavanserin on antipsychotic prescription and psychosis control,\u201d Rush University, 2023."},{"key":"3809_CR49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","volume":"362","author":"J Gu","year":"2024","unstructured":"Gu J, Qu Y, Shen Y, Zhou Q, Jiang Y, Zhu H (2024) Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database. J Affect Disord 362:742\u2013748","journal-title":"J Affect Disord"},{"issue":"12","key":"3809_CR50","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/13543784.2023.2288074","volume":"32","author":"B Dean","year":"2023","unstructured":"Dean B (2023) Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert Opin Investig Drugs 32(12):1113\u20131121","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"3809_CR51","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/ph17050610","volume":"17","author":"O Vasiliu","year":"2024","unstructured":"Vasiliu O, Budeanu B, C\u0103t\u0103nescu M-\u0218 (2024) The new horizon of antipsychotics beyond the classic dopaminergic hypothesis\u2014the case of the xanomeline\u2013trospium combination: a systematic review. Pharmaceuticals 17(5):610","journal-title":"Pharmaceuticals"},{"key":"3809_CR52","doi-asserted-by":"crossref","unstructured":"X. Guo, R. Deng, J. Lai, and S. Hu, \u201cIs muscarinic receptor agonist effective and tolerant for schizophrenia? A systematic review and meta-analysis,\u201d 2024.","DOI":"10.21203\/rs.3.rs-5387999\/v1"},{"key":"3809_CR53","doi-asserted-by":"crossref","unstructured":"L. Fu et al., \u201cM1\/M4 receptors as potential therapeutic treatments for schizophrenia: a comprehensive study,\u201d Bioorganic & Medicinal Chemistry, p. 117728, 2024.","DOI":"10.1016\/j.bmc.2024.117728"},{"key":"3809_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00002512-199303040-00004","volume":"3","author":"M Feinberg","year":"1993","unstructured":"Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335\u2013348","journal-title":"Drugs Aging"},{"issue":"6","key":"3809_CR55","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biom11060864","volume":"11","author":"CL Cioffi","year":"2021","unstructured":"Cioffi CL (2021) Inhibition of glycine re-uptake: a potential approach for treating pain by augmenting glycine-mediated spinal neurotransmission and blunting central nociceptive signaling. Biomolecules 11(6):864","journal-title":"Biomolecules"},{"issue":"7","key":"3809_CR56","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/biomedicines12071518","volume":"12","author":"L Raiteri","year":"2024","unstructured":"Raiteri L (2024) Interactions involving glycine and other amino acid neurotransmitters: focus on transporter-mediated regulation of release and glycine\u2013glutamate crosstalk. Biomedicines 12(7):1518","journal-title":"Biomedicines"},{"issue":"1","key":"3809_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","volume":"6","author":"SG Potkin","year":"2020","unstructured":"Potkin SG et al (2020) The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 6(1):1","journal-title":"NPJ Schizophr"},{"issue":"1","key":"3809_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/biomedicines13010085","volume":"13","author":"L Biso","year":"2025","unstructured":"Biso L, Carli M, Scarselli M, Longoni B (2025) Overview of novel antipsychotic drugs: state of the art, new mechanisms, and clinical aspects of promising compounds. Biomedicines 13(1):85","journal-title":"Biomedicines"},{"issue":"7","key":"3809_CR59","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/biomedicines11071977","volume":"11","author":"SR Kuvarzin","year":"2023","unstructured":"Kuvarzin SR, Sukhanov I, Onokhin K, Zakharov K, Gainetdinov RR (2023) Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders. Biomedicines 11(7):1977","journal-title":"Biomedicines"},{"issue":"6","key":"3809_CR60","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14740338.2024.2348561","volume":"23","author":"W Strube","year":"2024","unstructured":"Strube W, Wagner E, Luykx JJ, Hasan A (2024) A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective. Expert Opin Drug Saf 23(6):715\u2013729","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"3809_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3928\/02793695-20220112-02","volume":"60","author":"MA Sabra","year":"2022","unstructured":"Sabra MA, Hamdan-Mansour AM (2022) Using relapse prevention interventions to maintain remission and minimize relapse rates for individuals with schizophrenia: a scoping review. J Psychosoc Nurs Ment Health Serv 60(7):47","journal-title":"J Psychosoc Nurs Ment Health Serv"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03809-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03809-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03809-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:45:21Z","timestamp":1742370321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03809-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3809"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03809-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}